Does EDOXABAN Cause Hepatocellular carcinoma? 6 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Hepatocellular carcinoma have been filed in association with EDOXABAN (SAVAYSA). This represents 0.1% of all adverse event reports for EDOXABAN.
6
Reports of Hepatocellular carcinoma with EDOXABAN
0.1%
of all EDOXABAN reports
0
Deaths
4
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From EDOXABAN?
Of the 6 reports, 4 (66.7%) required hospitalization.
Is Hepatocellular carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EDOXABAN. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does EDOXABAN Cause?
Anaemia (663)
Cerebral infarction (419)
Gastrointestinal haemorrhage (378)
Renal impairment (359)
Cerebrovascular accident (337)
Dyspnoea (331)
General physical health deterioration (315)
Haematuria (312)
Fall (298)
Cardiac failure (272)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
Which EDOXABAN Alternatives Have Lower Hepatocellular carcinoma Risk?
EDOXABAN vs EDOXABAN TOSILATE
EDOXABAN vs EFALIZUMAB
EDOXABAN vs EFANESOCTOCOG ALFA
EDOXABAN vs EFAVIRENZ
EDOXABAN vs EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL